FOLD Cuts A Deal, SNTA On Watch, NanoString Makes Mega Leap, GALT Vaults

Amicus Therapeutics (FOLD: Quote) has entered into a collaboration with Biogen Idec (BIIB) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease.

The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease.

FOLD closed Tuesday's trading at $2.66, up 4.31%.

Conatus Pharmaceuticals Inc. (CNAT: Quote), which made its stock market debut as recently as July of this year, has initiated a phase II study of Emricasan in patients with severe alcoholic hepatitis.

This study is being conducted by the Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) Consortium consisting of the Mayo Clinic Rochester, Indiana University, and Virginia Commonwealth University in collaboration with the National Institute on Alcohol Abuse and Alcoholism.

CNTA closed Tuesday's trading 0.47% higher at $8.62.

Exelixis Inc. (EXEL: Quote) has initiated a phase III trial, dubbed CELESTIAL, comparing Cabozantinib with placebo in patients with advanced hepatocellular carcinoma who have previously been treated with Sorafenib. The primary endpoint for the trial is overall survival.

EXEL touched a new 52-week high of $5.64 on Tuesday before closing at $5.58.

Galectin Therapeutics (GALT: Quote) touched a new 52-week high of $8.71 on Tuesday before closing at $8.57 following the receipt of US patent for its compound GR-MD-02, a potential ground-breaking treatment for fatty liver disease. GR-MD-02 is currently under a phase 1 clinical trial in patients with fatty liver disease with advanced fibrosis.

We alerted readers to GALT in January of this year when it was trading around $2.46. Had you bought it then, you would have made a gain of 254% based on the new 52-week high.

See the article here:
FOLD Cuts A Deal, SNTA On Watch, NanoString Makes Mega Leap, GALT Vaults